ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome.
Level 5 - mechanism / opinion, no new human data
In vitro, structural, and computational laboratory study investigating molecular interactions
PubMed 34851659 · doi:10.1126/sciadv.abl8213
What was done
Investigators resolved the structure of the chimpanzee adenovirus vector ChAdOx1 and used computational modeling to simulate its molecular interactions with platelet factor 4 (PF4), a protein implicated in heparin-induced thrombocytopenia. They tested and validated binding between PF4 and three adenoviral vaccine vectors (ChAdOx1, HAdV-D26, and HAdV-C5) experimentally using surface plasmon resonance.
What was found
The abstract reports no specific numerical binding constants, kinetic rates, or charge measurements. It reports that all three adenoviruses deployed as SARS-CoV-2 vaccine vectors bound to PF4. Computational simulations demonstrated an electrostatic interaction mechanism between ChAdOx1 and PF4, which was experimentally confirmed by surface plasmon resonance showing stable complex formation between PF4 and the adenoviral vectors.
Why it matters
The study identifies a direct physical mechanism—electrostatic complex formation between adenoviral vectors and PF4—that helps explain the biological trigger for vaccine-induced thrombosis with thrombocytopenia syndrome.
Limits
This is purely a preclinical in vitro and in silico study without in vivo models or human clinical data. The abstract provides no quantitative binding metrics (such as Kd or stoichiometry). The findings explain a potential molecular interaction but do not account for host-specific factors that dictate why thrombosis with thrombocytopenia syndrome occurs only in an ultrarare subset of vaccinated individuals.
Cited by
- supports The AstraZeneca/Oxford COVID-19 vaccine uses a chimpanzee adenovirus vector to deliver DNA into the nucleus, where it is transcribed into mRNA.